Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac
Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac
Pfizer Inc (NYSE:PFE) has reportedly settled 10,000 lawsuits alleging it concealed the cancer risks associated with its Zantac heartburn medication, marking the largest resolution in the litigation.
據報道，輝瑞公司（紐約證券交易所代碼：PFE）已經和解了10,000起訴訟，指控其隱瞞了與Zantac胃灼熱藥物相關的癌症風險，這是該訴訟中最大的解決方案。
The agreements span various state courts across the U.S. but do not entirely mitigate the company's exposure to Zantac-related claims.
這些協議涵蓋美國各地的各個州法院，但並不能完全減少該公司面臨Zantac相關索賠的風險。
Financial specifics of the settlements have not been disclosed, Bloomberg noted, citing people familiar with the matter.
彭博社援引知情人士的話指出，和解協議的財務細節尚未披露。
Despite this significant resolution, the settlement does not completely absolve Pfizer from its Zantac-related legal challenges.
儘管有這項重要決議，但該和解協議並未完全免除輝瑞與贊塔克相關的法律挑戰。
Concerns surrounding potential liabilities stemming from Zantac-related litigation had led to a collective market value loss of approximately $45 billion among drugmakers in 2022.
對Zantac相關訴訟引發的潛在負債的擔憂導致製藥商在2022年集體市值損失約450億美元。
Last month, Sanofi SA (NASDAQ:SNY) announced an agreement in principle to settle approximately 4,000 lawsuits in the U.S. linked to the discontinued heartburn drug Zantac. Bloomberg added that the settlement will exceed $100 million.
上個月，賽諾菲公司（納斯達克股票代碼：SNY）宣佈了一項原則上協議，將在美國解決約4,000起與停產的胃灼熱藥物Zantac有關的訴訟。彭博社補充說，和解協議將超過1億美元。
In December 2022, U.S. District Judge Robin Rosenberg in Florida dismissed about 50,000 claims associated with GSK Plc (NYSE:GSK), Pfizer, Sanofi, and Boehringer Ingelheim, that claimed that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by solid science.
2022年12月，佛羅里達州的美國地方法院法官羅賓·羅森伯格駁回了與葛蘭素史克集團（紐約證券交易所代碼：GSK）、輝瑞、賽諾菲和勃林格英格翰有關的約50,000項索賠，這些索賠聲稱胃灼熱藥物Zantac導致癌症，因爲法官認爲這些指控沒有堅實的科學支持。
In 2020, the FDA confirmed the presence of NDMA in Zantac, leading to a nationwide recall. Subsequently, some manufacturers have reintroduced Zantac to the market with alternative active ingredients.
2020年，美國食品藥品管理局證實了Zantac中存在NDMA，導致全國範圍的召回。隨後，一些製造商將具有替代活性成分的Zantac重新推向市場。
Despite legal victories for the companies involved, challenges persist as thousands of Zantac-related cases await resolution in various courts across the United States.
儘管所涉公司在法律上取得了勝利，但挑戰仍然存在，因爲美國各地有成千上萬的與Zantac相關的案件有待解決。
Price Action: PFE shares are up 1.33% at $28.14 at last check Wednesday.
價格走勢：週三最後一次檢查時，PFE股價上漲1.33％，至28.14美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：此內容部分是在人工智能工具的幫助下製作的，並由Benzinga的編輯審閱和發佈。